Brain cancer patients demand public inquiry into chemotherapy scandal

News imageBBC A woman with straight brown hair in a grey and brown jumper is sat at a kitchen table looking at the cameraBBC
Becky Jones who had 11 years of chemotherapy for a cancer she did not have said treatment was "handed out like sweets"

Brain cancer patients who were given years of unnecessary chemotherapy are calling for a public inquiry, after a review found people were severely harmed under an NHS trust's care.

Some were misdiagnosed while others were told if they stopped temozolomide (TMZ) treatment they would die, despite this not being true.

The Royal College of Physicians (RCP) investigated 20 cases at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust.

The drug is typically meant to be taken for six months but in one case a patient of Prof Ian Brown was given more than 100 cycles of chemotherapy over a period of 13 years.

Becky Jones, who had 11 years of the treatment for a cancer she did not have, has told the BBC she was "absolutely disgusted" that "chemotherapy was dished out like it was sweets".

News imageUHCW University Hospital Coventry, a large white building with a circular building flanked by trees. There are some cars parked in front of the building and people walking outside it. UHCW
University Hospitals Coventry and Warwickshire NHS Trust has apologised

"I have two young children and to think once upon a time I might not have been there for their future kills me every day and it's all down to one person," the 34-year-old added.

She is one of more than 40 patients taking legal action against the NHS Trust. The mum-of-two was 21 when she was told she had a grade 4 glioblastoma and six to 12 months to live.

After more than 100 cycles of chemotherapy it was found she had never had a brain tumour and that her imaging was consistent with tumefactive demyelination, a less serious lesion.

She said of the report: "The findings are worse than I ever expected them to be.

"A national inquiry needs to happen and things need to be tightened up so it can't happen to anyone else."

Prof Brown, referred to as Dr Y in the RCP's report, did not take part in the review and refused to comment when approached by the BBC at his home.

University Hospitals Coventry and Warwickshire (UHCW) NHS Trust has apologised for "failures" within its neuro-oncology service under the care of the retired clinical oncologist.

Chief executive Professor Andy Hardy and trust chair Sue Noyes said in a statement: "This is far below the standards our patients deserve and that we expect. We let you down, and for that we offer our sincere apologies."

News imageSupplied Image shows a man in a white/pale pink shirt, opened at the collar. He is wearing a yellow baseball cap, back to front, and some grey hair is sprouting out the sides. He looks like he may be on holiday. His eyes are squinting towards the camera and he has a slight smile.Supplied
Prof Ian Brown, who retired in 2024, is referred to as Dr Y in the review

Brown was employed there from 1996 to 2024 and concerns over his practice were raised by colleagues when his patients were handed over to them when he retired in December 2023.

Medics found people on long-term repeated cycles of TMZ, against standard practice and national guidelines.

Some patients had also been left on treatment despite their cancer progressing, when moving to the best supportive care for their symptoms would have been a better choice.

More than 80 treated

TMZ, a chemotherapy drug that is sometimes used for glioblastoma and astrocytoma brain tumours, should usually be taken post radiotherapy for six cycles, usually over six months, but some patients have told the BBC they received it for many years.

The review warned there may be many more affected patients, with 83 receiving extended TMZ treatment between 2017 and 2023.

Overall, the RCP examined 20 cases of care under Prof Brown, though the number of patients affected, including those who have died, is higher.

Among other recommendations, the RCP said that any wider review of patients who received the treatment and have since died should be discussed with the Department of Health and Social Care.

"There is a large cohort of deceased patients who have received this non-standard chemotherapy regime, who may potentially have come to harm," the report said.

"To review every patient would be a significant and costly undertaking. The Trust should determine whether such a step is appropriate, and if so, discuss with the DHSC and/or NHS England how such a review would proceed."

Follow BBC Coventry & Warwickshire on BBC Sounds, Facebook, X and Instagram.